Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia

Mishra, Vineet; Gandhi, Khusaili; Roy, Priyankur; Hokabaj, Shaheen; Shah, Kanisha

doi:10.3126/jnhrc.v15i2.18158

Cited by 12 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They concluded that intravenous ferric carboxymaltose was safe and effective in pregnant women with iron deficiency anaemia. (7) In our study, there was hypersensitive reaction. The incidence was 30% in our study.…”

Section: Baselinesupporting

confidence: 45%

Short-Term Outcome of Intravenous Iron Therapy for Iron Deficiency Anaemia at Jnims, Imphal- A Preliminary Report

Ginzaniang¹,

Singh²,

Singh³

et al. 2018

jemds

View full text Add to dashboard Cite

BACKGROUND Iron deficiency anaemia (IDA) comprises of 50% of anaemia cases worldwide. The treatment consists of oral iron therapy and IV iron therapy. However, both of them may have their own side effects. Oral iron may have gastritis and constipation, while IV may have hypersensitive reaction. MATERIALS AND METHODS The study was conducted at the Department of Medicine, JNIMS, Imphal from July 2017 till March 2018. The study was an observational study. The aim of the study was to see the efficacy, indications and adverse effects of intravenous iron therapy in iron deficiency anaemia at JNIMS. The study included all patients with iron deficiency anaemia who received IV iron, either Ferric carboxymaltose or Iron isomaltoside during the study period. RESULTS Fifty-six patients of anaemia were diagnosed to have iron deficiency anaemia during the study period. Twenty patients were eligible for intravenous iron therapy. Remaining patients were on oral iron supplement. The commonest cause for IDA was heavy uterine bleeding (HUB) (50%) followed by haemorrhoids (30%). The indication for IV iron was commonest among patient with oral iron intolerance along with HUB (35%). The baseline haemoglobin level in our study was 6.24 ± 1.45 g/dL. Haemoglobin level at the end of 4 weeks and 3 months were 8.38 ± 1.34 g/dL and 12.98 ± 0.75 g/dL respectively. Six patients (30%) had palpitation, dizziness and breathlessness lasting for 5 minutes immediately after the infusion. All the patients could finish IV iron. CONCLUSION Intravenous iron therapy is an essential treatment modality for the iron deficiency anaemia. Even with minor hypersensitive reactions, all the patients could continue the treatment with IV iron. All the cases had improved haemoglobin level at 4 weeks and 3 months.

show abstract

Section: Baselinesupporting

confidence: 45%

Short-Term Outcome of Intravenous Iron Therapy for Iron Deficiency Anaemia at Jnims, Imphal- A Preliminary Report

Ginzaniang¹,

Singh²,

Singh³

et al. 2018

jemds

View full text Add to dashboard Cite

show abstract

“…In second and third trimesters, IV iron therapy is safe and generally favored over oral formulations due to fewer side effects and rapid correction of anemia . Ferric carboxymaltose is commonly used when treating second and third‐trimester pregnancy IDA given its comparable safety profile to iron sucrose while requiring fewer repeated applications due to higher iron dose with each administration . Since hypophosphatemia is a known side effect of ferric carboxymaltose, care should be taken to mitigate any exacerbating factors like vitamin D deficiency .…”

Section: Iron Deficiency Anemia In Pregnancymentioning

confidence: 99%

“…53,54 Ferric carboxymaltose is commonly used when treating second and third-trimester pregnancy IDA given its comparable safety profile to iron sucrose while requiring fewer repeated applications due to higher iron dose with each administration. [55][56][57] Since hypophosphatemia is a known side effect of ferric carboxymaltose, care should be taken to mitigate any exacerbating factors like vitamin D deficiency. 58 Data are increasing on the safety of other formulations in pregnancy including low-molecular-weight iron dextran.…”

Section: Iron Defi Cien C Y Anemia In Preg Nan C Ymentioning

confidence: 99%

The role of iron repletion in adult iron deficiency anemia and other diseases

Elstrott

Khan

Olson

et al. 2019

European J of Haematology

109

View full text Add to dashboard Cite

Iron deficiency anemia (IDA) is the most prevalent and treatable form of anemia worldwide. The clinical management of patients with IDA requires a comprehensive understanding of the many etiologies that can lead to iron deficiency including pregnancy, blood loss, renal disease, heavy menstrual bleeding, inflammatory bowel disease, bariatric surgery, or extremely rare genetic disorders. The treatment landscape for many causes of IDA is currently shifting toward more abundant use of intravenous (IV) iron due to its effectiveness and improved formulations that decrease the likelihood of adverse effects. IV iron has found applications beyond treatment of IDA, and there is accruing data about its efficacy in patients with heart failure, restless leg syndrome, fatigue, and prevention of acute mountain sickness. This review provides a framework to diagnose, manage, and treat patients presenting with IDA and discusses other conditions that benefit from iron supplementation.

show abstract

“…The side effect includes metallic taste, anaphylaxis, nausea, dizziness and local irritation. 4,5 Ferrous carboxymaltose (FCM) FCM was FDA approved in 2004. The single dose of Iv FCM, not exceeding 1500 mg of iron (30 ml) per day was given.…”

Section: Iron Sucrose (Is)mentioning

confidence: 99%

Comparing the Safety between Ferrous Carboxymaltose and Iron Sucrose Therapy in Iron Deficiency Anemia during Pregnancy in Obstetrics and Gynecology Ward at Tertiary Care Hospital, Jaipur

K¹,

Singh²,

Agrawal³

2019

IJOPP

View full text Add to dashboard Cite

Background: Pregnancy is the most vulnerable condition prone for anemia (most commonly iron deficiency anemia). Hence requires drug therapy for iron store replenishment. Comparing the safety between ferrous carboxymaltose and iron sucrose therapy in iron deficiency anemia during pregnancy in obstetrics and gynecology ward at a tertiary care hospital. Methods: A prospective observational single centered study was conducted on 60 pregnant women who were diagnosed with iron deficiency anemia in the department of obstetrics and gynecology at tertiary care teaching hospital. The subjects were divided into two groups, first group was administered iron sucrose 200mg and second group was administered ferrous carboxymaltose 500mg. The relative incidence of drug administrative adverse event was low in Ferrous Carboxymaltose than compare to Iron Sucrose. Result: The adverse event occurred in 3.33% for Ferrous Carboxymaltose and 13.33% for Iron Sucrose. The mean rise of hemoglobin was 2.92 g/l for Ferrous Carboxymaltose and 1.08 g/l for iron sucrose. Conclusion: In this study it was found that Ferrous carboxymaltose is safer in comparison to the Iron sucrose among the pregnant women with Iron deficiency anemia.

show abstract

Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia

Cited by 12 publications

References 15 publications

Short-Term Outcome of Intravenous Iron Therapy for Iron Deficiency Anaemia at Jnims, Imphal- A Preliminary Report

Short-Term Outcome of Intravenous Iron Therapy for Iron Deficiency Anaemia at Jnims, Imphal- A Preliminary Report

The role of iron repletion in adult iron deficiency anemia and other diseases

Comparing the Safety between Ferrous Carboxymaltose and Iron Sucrose Therapy in Iron Deficiency Anemia during Pregnancy in Obstetrics and Gynecology Ward at Tertiary Care Hospital, Jaipur

Contact Info

Product

Resources

About